Portal Biotech Raises $35 Million Series A, Leveraging AI to Deliver the World’s First Full-Length Single-Molecule Protein Sequencer
Notified -
Globe Newswire30-06-2025, 22:28
New Long-term Safety Data from the Completed Phase 3 SOLARIS Trial Support the Potential of Olanzapine LAI (TEV-'749) as the First Long-Acting Olanzapine Treatment Option for Schizophrenia with No PDSS Observed 21-09-2025, 09:15
